How effective is tacrolimus in managing dry eye secondary to Sjogren syndrome?

Label:chem

Topic
Sjogren syndrome is an autoimmune disorder that often leads to dry eye due to reduced tear production.
Answer
Tacrolimus 0.03% eye drops were found to be as effective as cyclosporine 0.05% in improving symptoms and signs of dry eye secondary to Sjogren syndrome. A study showed significant improvements in ocular surface stability and reduced reliance on artificial tears, with no significant differences between the two treatments.
Return to Home Chemical List
Knowledge you may be interested in
What are the common side effects of topical tacrolimus in ocular conditions? How does tacrolimus compare to other treatments in terms of efficacy for vernal keratoconjunctivitis (VKC)? What is the role of tacrolimus in the management of ocular surface diseases? What are the potential targets of allosamidin in asthma? What is the anti-asthmatic activity of allosamidin and demethylallosamidin? How does allosamidin affect chitinase production in Streptomyces? What are the biological activities of allosamidin in Streptomyces? How does allosamidin inhibit family 18 chitinases? What is the structure and biosynthesis of allosamidin? How does calyculin A (cal A) affect the kinetics of DNA repair foci formation in irradiated cells? What are the advantages of using tacrolimus over corticosteroids in ocular graft-versus-host disease (GVHD)? How does tacrolimus perform in treating adenoviral corneal subepithelial infiltrates (SEIs)? What is the role of tacrolimus in preventing acute endothelial graft rejection after penetrating keratoplasty (PKP)? What is the role of Olprinone (OLP) in hepatoprotection after partial hepatectomy and endotoxin-induced liver injury? How does Olprinone (OLP) affect survival rates in rats subjected to partial hepatectomy and LPS treatment? What is the effect of Olprinone (OLP) on pro-inflammatory cytokines and chemokines in the liver? How does Olprinone (OLP) influence inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in the liver? What histopathological changes are observed in the liver after treatment with Olprinone (OLP)? How does Olprinone (OLP) affect NF-κB activation in hepatocytes? What are the potential clinical implications of using Olprinone (OLP) for hepatoprotection?